 |
SV Life Sciences Fund III (Exited Investments)SVLSF III closed in 2003 with total commitments of $393 million (plus $8 million of co-investments committed by partners and individuals affiliated with SVLS). As at 31 March 2010 the Fund had invested $374 million in 39 portfolio companies. To go to individual portfolio companies websites please click on company logo. SV Life Sciences Fund III (SVLSFIII)
Alantos Pharmaceuticals: US - Exited
First investment: 2003 - Early Stage Alantos was a chemistry-driven company seeking to discover and develop drugs targeted at osteoarthritis and inflammatory processes. The company attempts to fast follow others to reduce risk. 
Allegiance Hospice Group: US - Exited
First investment: 2005 - Start Up Allegiance Hospice is based in Lowell, MA, focused on providing hospice services to patients primarily in long- term care facilities within the New England market. 
Avera Pharmaceuticals: US - Exited
First investment: 2004 - Early Stage Avera is based in San Diego, CA and focused on the development of small molecule drugs for the treatment of diseases affecting the central nervous system (CNS). Key programs are Alzheimer’s disease, schizophrenia associated cognition deficits, IBS, and OAB, and developing an ultra-short acting anaesthesia compound. 
Celldex/Lorantis: UK - Exited
First investment SVLSF II: 2001 - Seed First investment SVLSF III: 2003 - Seed Celldex merged with the quoted company Avant Immunotherapeutics (ticker:'AVAN') in March 2008. Celldex, formerly a wholly owned subsidiary of Medarex Inc., merged with Lorantis Ltd in 2005. Celldex pursues immunological approaches to the treatment of cancers, infectious disease and immunological disorders. 
Cellutions: US - Exited
First investment: 2004 - Seed Cellutions is based in Duluth, GA, (TIF)is developing a minimally invasive approach for addressing cellulite and its appearance on the skin. 
Dynogen Pharmaceuticals: US - Exited
First investment: 2004 - Early Stage Dynogen is a neuroscience-based company focused on genito-urinary (GU) and gastro-intestinal (GI) disorders. The company is using its knowledge of neurology and GU/GI disorders to build a pipeline of clinical candidates. 
Eunoe: US - Exited
First investment: 2003 - Expansion Eunoe was a treatment of neurological disorders through cerebrospinal fluid management (CSF). 
GlycoFi: US - Exited
First investment: 2002 - Start Up GlycoFi was a production and engineering of therapeutics proteins. 
Gyros: Sweden - Exited
First investment: 2002 - Start Up Gyros, located in Uppsala, Sweden, has developed a proprietary microfluidics technology for processing and analysis of proteins and blood samples. Laboratory processes are integrated into a client specific disc (CD) format. The CD is processed and its contents analysed on software controlled instrumentation. 
Insulet: US - Exited
First investment SVLSF III: 2004 - Late Stage Insulet based in Bedford, MA, Insulet is designing and developing products that provide superior treatment for people with diabetes. The Company’s first commercial product is a wireless 3-day insulin pump. 
LipoSonix: US - Exited
First investment SVLSF II: 2001 - Seed First investment SVLSF III: 2003 - Seed LipoSonix based in Bothell, WA, was developing a product to use non-invasive, high intensity focused ultrasound to ablate unwanted subcutaneous cells as a non-invasive alternative to liposuction for body sculpting. Funded through the innovation factory. 
Patient Care: US - Exited
First investment: 2002 - Buyout Patient Care based in Orange, NJ, is one of the largest independent home health agencies. 
PowderMed: UK - Exited
First investment: 2004 - Early Stage PowderMed developed therapeutic DNA vaccines in the areas of chronic viral diseases and cancer. 
Rinat Neuroscience: US - Exited
First investment: 2003 - Early Stage Rinat developed proteins for the treatment of diseases and disorders of the nervous system. 
Sapphire Pharmaceuticals: US - Exited
First investment: 2004 - Early Stage Helsinn is developing small molecule drugs based on the biology of ghrelin,a gut peptide known to stimulate appetite. The lead compound is in Ph II for cancer cachexia; a second compound has completed an initial clinical study and is moving toward Ph II for post-operative ileus. Additional indications are being explored for follow-on compounds. Formerly known as Rejuvenon. 
Synarc: US - Exited
First investment: 2004 - Late Stage Synarc provides centralized medical imaging services and international subject-recruitment facilities dedicated exclusively to global clinical trials. 
| |
